Li et al. found that sintilimab plus DEB-BACE in NSCLC was also superior to that with monotherapy of PD-1/PD-L1 blockade as first-line therapy (Li et al., 2021). This evidence concerns the gene CD274 and non-small cell lung carcinoma.